xalkori
pfizer europe ma eeig - crizotinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
torisel
pfizer europe ma eeig - Темсиролимус - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastična sredstva - Почечно-stanični carcinomatorisel indiciran za prva linija terapije kod odraslih pacijenata s česta почечно-клеточным raka (pkr), koji imaju najmanje tri od šest prognostičke faktore rizika . Мантийно-stanica lymphomatorisel indiciran za liječenje odraslih bolesnika s ponavljajućom i / ili vatrostalne мантийно-stanica limfoma (Μl).
talzenna
pfizer europe ma eeig - talazoparib - neoplazme dojki - antineoplastična sredstva - talzenna prikazan kao monoterapija za liječenje odraslih bolesnika s зародышевой linije gena brca1/2 mutacije, koje imaju her2 negativan lokalno-održao ili метастатического raka dojke . patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. pacijenti s receptore hormona (h)-pozitivan rak dojke moraju biti obrađene do эндокринно-terapija, ili se smatraju neprikladnim za endokrine terapije na temelju.
lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, ne-malih stanica pluća - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
vizimpro
pfizer europe ma eeig - dacomitinib monohidrat - karcinom, ne-malih stanica pluća - antineoplastična sredstva - vizimpro, kao monoterapija, je propisan za prva linija terapije kod odraslih pacijenata sa lokalno-održao ili метастатического немелкоклеточного raka pluća (НМРЛ) s epidermalnog faktora rasta (egfr) aktiviraju mutacije.
staquis
pfizer europe ma eeig - crisaborole - dermatitis, atopic - ostali dermatološki pripravci - staquis naznačeno za liječenje blage do umjerene atopijski dermatitis u odraslih i pedijatrijska bolesnika od 2-x godina s ≤ 40% površine tijela (bsa) utjecaj.
daurismo
pfizer europe ma eeig - glasdegib maleate - leukemija, mieloidna, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresivi - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
edronax 4 mg tablete
pfizer croatia d.o.o., slavonska avenija 6, zagreb, hrvatska - reboksetin metansulfonat - tableta - 4 mg - urbroj: jedna tableta sadrži 4 mg reboksetina u obliku reboksetin metansulfonata